Company intelligence / Profile preview

Karuna Therapeutics

Boston, Massachusetts, USAkarunatx.com ↗

Ownership: Public · KRTX
Development stage: Other

Overview

KarXT has demonstrated strong efficacy across multiple Phase III trials for schizophrenia with differentiated safety/tolerability profile versus standard antipsychotics. The NDA for adult schizophrenia was accepted by the FDA with potential approval expected late September 2024. Additional registrational trials are ongoing for adjunctive use in schizophrenia and psychosis in Alzheimer’s disease.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (notably muscarinic receptor modulators such as xanomeline-trospium)TRPC4/5 inhibitors
Industry: Biotech

Partnerships

Collaboration with PsychoGenics on KAR–501; previously partnered/inlicensed from Goldfinch Bio estate for KAR–2618

Beyond the preview

Go deeper on Karuna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karuna Therapeutics.